期刊
TRANSPLANTATION
卷 106, 期 6, 页码 1279-1287出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/TP.0000000000004006
关键词
-
资金
- Takeda Science Foundation
- JSPS KAKENHI [18K08325/21K08391]
Unrelated cord blood (UCB) and haploidentical related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) are alternative options for treating patients without a HLA-matched donor. This study compared the outcomes of UCB and PTCy-haplo transplantation in hematological malignancy patients and found that overall survival was comparable between the two groups. Neutrophil and platelet engraftment were delayed in the UCB group, but nonrelapse mortality risk and graft-versus-host disease incidence were similar between the groups. UCB transplantation showed a lower relapse rate in acute myeloid leukemia patients.
Background. Unrelated cord blood (UCB) and haploidentical related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) have become alternative options to treat patients with hematological malignancies without a HLA-matched donor. Methods. We conducted a retrospective study using registry data from the Kyoto Stem Cell Transplantation Group for patients with hematological malignancies who received their first allogeneic hematopoietic cell transplantation using a single UCB unit (n = 460) or PTCy-haplo (N = 57) between 2013 and 2019. Results. We found that overall survival in the UCB group was comparable to that in the PTCy-haplo group (hazard ratio, 1.00; 95% confidence interval, 0.66-1.52), although neutrophil and platelet engraftment were significantly delayed. Nonrelapse mortality risk and the incidence of graft-versus-host disease in the UCB group were also comparable to those in the PTCy-haplo group. Although the relapse risk was similar between the UCB group and the PTCy-haplo group regardless of the disease risk, acute myeloid leukemia patients benefit from UCB transplant with a significantly lower relapse rate (hazard ratio, 0.38; 95% confidence interval, 0.18-0.76). Conclusions. UCB transplant gives outcomes comparable to PTCy-haplo transplant, and both UCB and PTCy-haplo units are suitable as alternative donor sources for patients without an HLA-matched sibling or unrelated donor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据